PD-1 inhibitors in patients with Hodgkin lymphoma
Author:
Funder
AbbVie
Merck
Takeda Pharmaceutical Company
Roche
Janssen Pharmaceuticals
Amgen
Bristol-Myers Squibb
Gilead Sciences
Publisher
Elsevier BV
Reference11 articles.
1. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome;Roemer;J Clin Oncol Off J Am Soc Clin Oncol,2016
2. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma;Chen;J Clin Oncol,2017
3. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial;Younes;Lancet Oncol,2016
4. Immunotherapy in Hodgkin lymphoma: present status and future strategies;Vassilakopoulos;Cancers,2019
5. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial;Shi;Lancet Haematol,2019
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Negative Immune Checkpoint Inhibitors;Pharmaceutics;2025-05-28
2. Development of an LC–TOF/MS Method to Quantify Camrelizumab in Human Serum;Molecules;2024-10-14
3. Histone deacetylase inhibitor and PD‑1 blockade synergistically inhibit B‑cell lymphoma progression in mice model by promoting T‑cell infiltration and apoptosis;Oncology Reports;2024-08-07
4. Therapeutic challenges in peripheral T-cell lymphoma;Molecular Cancer;2024-01-04
5. CNS lymphoma masquerading as stroke: Cases report and literature review;Journal of Cellular and Molecular Medicine;2023-11-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.7亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2025 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3